Genedrive PLC MT-RNR1 ID kit adopted for routine use in Brighton (5986V)
04 Dicembre 2023 - 2:13PM
UK Regulatory
TIDMGDR
RNS Number : 5986V
Genedrive PLC
04 December 2023
genedrive plc
("genedrive" or the "Company")
Royal Sussex County Hospital, Brighton adopts the Genedrive(R)
MT-RNR1 ID Kit for routine use
Further expansion of hearing loss test into the NHS
genedrive plc (AIM: GDR), the point of care Pharmacogenetic
testing company, announces the Genedrive(R) MT-RNR1 ID Kit is now
in routine use in the Trevor Mann Baby Unit ("TMBU") at the Royal
Sussex County Hospital ("RSCH"), part of University Hospitals
Sussex NHS Foundation Trust. This site is the second NHS Trust in
the country to be using the Genedrive test for antibiotic induced
hearing loss ("AIHL").
Each year approximately 450 babies are admitted to the neonatal
unit in Brighton. The simple, non-invasive test will be used
routinely to guide treatment prescription within the unit from
today, 4 December 2023.
Inspiration Healthcare and Genedrive have been working closely
with the team at the TMBU, providing training and support, to
ensure the smooth implementation of the pharmacogenetic point of
care test into the neonatal admission process. Every mother and
child that comes to RSCH, will now have access to the life-changing
test, should it be required.
James Cheek, Chief Executive Officer of genedrive plc, said:
"Both children and parents in Sussex will have their lives and
patient pathways enhanced by having access to this test. It also
brings peace of mind and support to clinicians in very stressful
circumstances to make the right decision for the patient. On a
wider scale, it's great to see how rapid Pharmacogenetics testing
is transforming healthcare in time-critical settings, and improving
patient safety."
For further details, please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a pharmacogenetic testing company developing
and commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge which circumvents the requirement for cold chain
logistics by providing temperature stable reagent test kits for use
on their proprietary test platform. This test allows clinicians to
make a decision on antibiotic use within 26 minutes, ensuring vital
care is delivered with no negative impact on the patient
pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFSAFDLEDSESE
(END) Dow Jones Newswires
December 04, 2023 08:13 ET (13:13 GMT)
Grafico Azioni Genedrive (LSE:GDR)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Genedrive (LSE:GDR)
Storico
Da Set 2023 a Set 2024